• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the editor in response to the commentary, "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.

作者信息

Leder Benjamin Z, Tsai Joy N, Burnett-Bowie Sherri-Anne, Bouxsein Mary L, Neer Robert M

机构信息

Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

出版信息

Bone. 2016 Aug;89:73-74. doi: 10.1016/j.bone.2016.04.026. Epub 2016 May 5.

DOI:10.1016/j.bone.2016.04.026
PMID:27157641
Abstract
摘要

相似文献

1
Letter to the editor in response to the commentary, "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.致编辑的信：回应评论文章《甲状旁腺激素与抗吸收药物的联合应用：相加效应还是双能X线吸收仪的修饰作用》
Bone. 2016 Aug;89:73-74. doi: 10.1016/j.bone.2016.04.026. Epub 2016 May 5.
2
Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics".
Bone. 2016 Aug;89:75-76. doi: 10.1016/j.bone.2016.04.027. Epub 2016 Apr 30.
3
Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.评论：甲状旁腺激素（PTH）与抗吸收药物的联合使用：相加效应还是双能X线吸收测定法的修饰作用。
Bone. 2016 May;86:139-42. doi: 10.1016/j.bone.2016.02.009. Epub 2016 Mar 2.
4
Letter to the Editor: Combination Treatment With Teriparatide and Denosumab in Osteoporosis.致编辑的信：特立帕肽与地诺单抗联合治疗骨质疏松症
J Clin Endocrinol Metab. 2016 Aug;101(8):L80-1. doi: 10.1210/jc.2016-2343.
5
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.地诺单抗与特立帕肽在绝经后骨质疏松症中的转换（DATA-Switch研究）：一项随机对照试验的扩展
Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2.
6
Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.在DATA（地诺单抗与特立帕肽给药）研究随机对照试验中，绝经后女性接受特立帕肽、地诺单抗或两者联合治疗的疗效。
J Clin Densitom. 2016 Jul-Sep;19(3):346-51. doi: 10.1016/j.jocd.2016.01.004. Epub 2016 Feb 15.
7
Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.特立帕肽与地诺单抗对完整甲状旁腺激素及骨形成指标的不同影响：AVA骨质疏松症研究
J Clin Endocrinol Metab. 2016 Apr;101(4):1353-63. doi: 10.1210/jc.2015-4181. Epub 2016 Feb 9.
8
The role of teriparatide in sequential and combination therapy of osteoporosis.特立帕肽在骨质疏松症序贯及联合治疗中的作用。
Swiss Med Wkly. 2014 Jun 4;144:w13952. doi: 10.4414/smw.2014.13952. eCollection 2014.
9
[Combination or sequential treatment using PTH and anti-resorption therapies].
Clin Calcium. 2012 Mar;22(3):415-20.
10
Reply to Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".
J Clin Endocrinol Metab. 2020 May 1;105(5). doi: 10.1210/clinem/dgz123.

引用本文的文献

1
The Notch pathway regulates the bone gain induced by PTH anabolic signaling.Notch 通路调节 PTH 合成代谢信号诱导的骨量增加。
FASEB J. 2022 Mar;36(3):e22196. doi: 10.1096/fj.202101807R.
2
MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.MMP14 是破骨细胞中 PTH 信号的一个新靶点，通过调节可溶性 RANKL 的产生来控制吸收。
FASEB J. 2018 May;32(5):2878-2890. doi: 10.1096/fj.201700919RRR. Epub 2018 Jan 17.